Advanced-stage (FIGO III-IV) epithelial ovarian cancer: Multivariate analysis of prognostic factors in an area without a tertiary referral oncology center. A population-based study

Onkologie

Volumn 22, Issue 5, 1999, Pages 406-410

  Petignat, P ^a   Gaudin, G ^a   Vajda, D ^a   Stalder, M ^b   Rey, J P ^b   Faggiano, F ^b   De Weck, D ^b   Joris, F ^b   Obrist, Reto ^b  

^a Hopital de Sion   (Switzerland)

^b Institut Central des Hopitaux Valaisans   (Switzerland)

Author keywords

Chemotherapy; Cytoreductive surgery; DNA ploidy; Epithelial ovarian cancer; Survival time

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PLOIDY; POPULATION RESEARCH; PROGNOSIS; RISK FACTOR; SWITZERLAND; TREATMENT OUTCOME;

EID: 0032756586     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026990     Document Type: Article

References (21)

1. Joris F, Faggiano F, de Weck D: Le cancer en Valais: 1989-1993. Sierre, Schoechli, 1997 pp 104-105.
2. Omura GA. Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, Park RC: Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma:The Gynecology Oncology Group experience. J Clin Oncol 1991;9:1138-1150.
3. Alberts DS, Dahlberg S, Green SJ, Garcia D, Hannigan EV, O'Toole R, Stock-Novack D, Surwit EA, Malviya VK, Jolles CJ: Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophospbamide in stage III (sub-optimal) and IV ovarian cancer. Cancer 1993;71: 618-627.
4. Del Campo JM, Felip E, Rubio D, Vidal R, Bermejo B, Colomer R, Zanon V: Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. Gynecol Oncol 1994;57:27-32.
5. Rice LW, Mark SD, Berkowitz RS, Goff BA, Lage JM: Clinicopathologic variables, operative characteristics and DNA ploidy in predicting outcome in ovarian epithelial carcinoma. Obstet Gynecol 1995;86: 379-385.
6. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA: Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983; 31:1333-1335.
7. Kosary CL: FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: An analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Sem Surg Oncol 1994;10:31-46.
8. Baker TR, Piver MS, Hempling RE: Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin and cyclophosphamide therapy in advanced ovarian adenocarcinoma. Cancer 1994;74:656-663.
9. Badwe RA, Patil PK, Bhansali MS, Mistry RC, Juvekar RR, Desai PB: Impact of age and sex on survival after curative resection for carcinoma of the esophagus. Cancer 1994;74:2425-2429.
10. Baak JP, Lindeman J, Overdiep SH, Langley FA: Disagreement of histopathological diagnosis of different pathologists in ovarian tumors - with some theoretical considerations. Eur J Obstet Gynecol Reprod Biol 1982;13:51-55.
11. Baak JP, Langley FA, Talerman A, Delemarre JF: Interpathologist and intrapathologist disagreements in ovarian tumor grading and typing. Anal Quant Cytol Histol 1986;8:354-357.
12. Kaern J, Trope CG, Kristensen GB, Tveit KM, Pettersen EO: Evaluation of deoxyribonucleic acid ploidy and S-phase fraction as prognostic parameters in advanced epithelial ovarian carcinoma: A prospective study. Am J Obstet Gynecol 1994;170: 479-487.
13. Brescia RJ, Barakat RA, Richard AB, Beller U, Frederickson G, Suhrland MJ, Dubin N, Demopoulos RI: The prognostic significance of nuclear DNA content in malignant epithelial tumors of the ovary. Cancer 1990;65:141-147.
14. Friedlander ML, Hedley DW, Taylor JW, Russell P, Coates AS, Tattersall MH: Influence of cellular DNA content on survival in advanced ovarian cancer. Cancer Res 1984;44:397-400.
15. Khoo SK, Battistutta D, Hurst T, Sanderson B, Ward BG, Free K: The prognostic value of clinical, pathologic, and biologic parameters in ovarian cancer. Cancer 1993;72:531-537.
16. Kaern J, Trope CG, Kristensen GB, Tveit KM, Pettersen EO: Evaluation of deoxyribonucleic acid ploidy and S-phase fraction as prognostic parameters in advanced epithelial ovarian carcinoma: A prospective study. Am J Obstet Gynecol 1994;170: 479-487.
17. Pfisterer J, Kommoss F, Sauerbrei W, Renz H, du Bois A, Kiechle-Schwarz M, Pfeiderer A: Cellular DNA content and survival in advanced ovarian carcinoma. Cancer 1994;74:2509-2515.
18. Gajewski WH, Fuller AF, Pastel-Ley C, Flotte TJ, Bell DA: Prognostic significance of DNA content in epithelial ovarian cancer. Gynecol Oncol 1994; 53:5-12.
19. Barnabei VM, Miller DS, Bauer KD, Murad TM, Rademake AW, Lurain JR: Flow cytometric evaluation of epithelial ovarian cancer. Am J Obstet Gynecol 1990;162:1584-1592.
20. Bertelson K: Tumor reduction surgery and long-term survival in advanced ovarian cancer: A DACOVA study. Gynecol Oncol 1990;38:203-209.
21. Lawton FG, Hacker NF: Surgery for invasive gynecologic cancer in the elderly female population. Obstet Gynecol 1990;76:287-289.